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In 2003, Gottesman and Gould advocated using the endophenotype concept in psychiatry genetics;
describing it as a measurable component “along the pathway between disease and distal genotype”
(p. 636). Especially in schizophrenia research, the idea of endophenotypes has gathered a wide
following. Meehl’s definition of schizotaxia [Ref. (1), p. 829], as “an ‘integrative neural defect’ as the
only direct phenotypic consequence produced by the genetic mutation” and “This neural integrative
defect [: : :] is all that can properly be spoken of as inherited. The imposition of a social learning
history upon schizotaxic individuals results in a personality organizationwhich I shall call, following
Rado, the schizotype” (p. 830; my emphasis) reminds clearly of the aforementioned endophenotype
description.
Although there are a number of ongoing debates regarding the nature of schizotypy, its dis-
tribution throughout the population and its relation with schizophrenia, a few elements may be
considered “agreed upon”: (1) schizotypy is a latent trait (partly) harboring individual risk for
schizophrenia (2). (2) Schizotypy is (partly) influenced by genes considered relevant for schizophre-
nia; q.v. (3). (3) Schizotypic variance is best explained through gene–environment interactions of a
kind also relevant for schizophrenia (4). (4) Schizotypy shares a factor-structure with symptoms
of schizophrenia; with the most commonly replicated factors being the positive, negative, and
disorganized facets (5, 6). It therefore appears that schizotypy and schizophrenia qualitatively share
various similarities, albeit in a quantitatively different fashion.
It is not surprising that a number of measures considered endophenotypes of schizophrenia [q.v.
(7)] have also been shown to be associated with schizotypy (8). The question at hand (whether
schizotypy per semay qualify as a suitable endophenotype for schizophrenia) has, to my knowledge,
not been answered as yet. I have briefly argued thusly elsewhere (9) and will, here, further elaborate
on this and continue discussing the implications of the debated link between schizophrenia-genetics
and schizotypy in an attempt to provide a suitable answer to this question.
First, it is necessary to distinguish two pairs of entities: on the one hand, although often used
pseudo-synonymously, schizophrenia and psychosis are not the same. Schizophrenia is a psychotic
disorder; featuring psychosis as a primary phenomenon, but being defined furthermore by having
Krankheitswert. It has been shown repeatedly that (extremely) high schizotypic features and/or
psychotic experiences are not limited to the clinical domain and, contrapositively, that psychotic
experiences are found with considerably higher prevalence within the population [between 30
and 70% (10, 11)] than possible, if existing only in patient groups. Furthermore, it has been
convincingly argued [review in Ref. (12)] that individuals, christened “happy schizotypes” (13), with
considerably high positive schizotypy and often repeated psychotic experiences but significantly
lower negative/disorganized schizotypic features (compared to the population!) are not only “not
sick” but actually benefit from these experiences and are “more healthy.”
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The second necessary distinction is between positive and neg-
ative/disorganized schizotypy: it is often stated that “negative
schizotypy is the most heritable,” although this is better amended
to “most heritable in biological relatives of schizophrenics” [q.v.
(14)]. In the population, heritability estimates do not differ
between positive and negative schizotypy, and the data suggest
that the two facets are influenced genetically by two distinct
latent genetic factors (15). It would, thus, seem that while posi-
tive schizotypy is the underlying dimension explaining psychotic
features, it is not necessarily related to Krankheitswert. Nega-
tive schizotypy, however, appears closely related to schizophrenia
regarding its heritability as well as amajor factor that differentiates
“happy schizotypes” from schizophrenic patients.
Returning to endophenotypes, Gottesman and Gould (16)
clearly state that configured self-report data may also constitute
an endophenotype. They propose five criteria that qualify an
endophenotype. I shall aim to show that schizotypy meets these
criteria:
(1) Schizotypy is quite clearly associated with the clinical con-
dition of schizophrenia. Apart from aforementioned simi-
larities, patients with schizophrenia have repeatedly shown
to have higher values in schizotypy (17), and schizotypy is
elevated more highly in schizophrenic patients than in those
with other psychotic disorders (18).
(2) Schizotypy is heritable (~50%) (15); although there are dif-
ferences between individual schizotypy facets; with neg-
ative schizotypy being most highly heritable in patients’
relatives (14).
(3) Schizotypy as a stable trait with high re-test reliability does not
solely manifest during acute phases of illness [9, 19]. There
are, however, intraindividual variations in acute schizotypal
sensitivities, which are explained (mostly) by environmental
influences, whereby interindividual differences in susceptibil-
ity to environmental influences is again a major factor of trait
schizotypy (4, 19, 20). This is unsurprising when dealing with
complex traits and strengthens the case for (state) schizotypy.
(4) Schizotypy co-segregates with schizophrenia; i.e.,
schizophrenic relatives of schizophrenic patients have
higher values in (especially negative) schizotypy than healthy
relatives of schizophrenic patients (q.v., criterion 1).
(5) Healthy biological relatives (especially offspring) of
schizophrenic patients have repeatedly been shown to
have higher values in (especially negative) schizotypy (14),
and offspring of healthy but highly schizotypic individuals
have greater risk of developing schizophrenia (21, 22).
It should be emphasized that especially heritability, co-
segregation, and familial association are key points that differ-
entiate between “true” endophenotypes and “mere” biomarkers
or intermediate phenotypes [e.g., Ref. (23)]. The strong associa-
tions found between schizotypy and schizophrenia regarding the
respective criteria 2, 4, and 5, thus, make a strong case toward the
acceptance of psychometric schizotypy as an endophenotype of
schizophrenia.
There are, however, a number of findings that need further
discussion before a final conclusion may be drawn. (1) A number
of genetic factors associated with schizotypy are no longer consid-
ered relevant in schizophrenia genetics. (2) A number of genetic
factors associated with schizophrenia are not (or even inversely)
associated with schizotypy.
To address these points, it is necessary to keep the aforemen-
tioned distinctions “psychosis vs. schizophrenia” and “positive vs.
negative/disorganized schizotypy” in mind. In other words, it is
expected that all schizophrenics are highly schizotypic, but not all
highly schizotypic individuals are schizophrenic; both parts of this
expectation hold true [q.v. (13)].
This latter observation, referred to by Claridge (24) as benign
schizotypy, is an important point to consider with respect to
the aforementioned two “critical points.” There is currently no
general consensus regarding the exact nature of schizotypy in
the entire population or the relation with schizophrenia genes.
The Meehlian model proposes the group of schizotypes to be
discrete, making up 10% of the population and defined qua the
presence of (few) specific genetic risk factors. The more com-
mon view in schizotypy research, however, is that schizotypy
is continuously distributed throughout the population and is
genetically based on a multitude of genetic loci, whereof each
have only small effect sizes, but these effects interact (9) and
are additive (25); similar to recent conceptions of schizophre-
nia genetics (26, 27). This would give rise to an Eysenckian
view (28) that schizophrenia be equal to extremely high schizo-
typy (or rather psychoticism in the Eysenckian model of per-
sonality) [q.v. (29)]. This view is, however, incompatible with
the existence of benign schizotypy or happy schizotypes. I have,
thus, suggested and discussed in more detail (3, 4) that the fully
dimensional model of schizotypy (24) has the best fit regarding
more recently shown genetic associations of both schizotypy and
schizophrenia.
This model explains the discrepancies mentioned above in
my “critical points”: it proposes that schizotypy is normally dis-
tributed in the population, but interacts with a second dimen-
sion; i.e., health or resilience. High schizotypy is in and of
itself, thus, not equal to schizophrenia; when coinciding with
low health/resilience, however, schizophrenia is the outcome.
Schizophreniamay therefore be viewedupon as resulting from low
resilience to the high [probably dopaminergic; q.v. (30)] strain on
the nervous system conferred by (positive) schizotypy. The lack
of association between individual schizotypy-related genetic vari-
ants and schizophrenia (e.g., the COMT-polymorphism rs4680)
is therefore not surprising and does not disqualify schizotypy as
an endophenotype. This is quite simply due to the fact that small
effects of single schizotypy-related polymorphismsmay disappear
in case–control schizophrenia studies; under the assumption of
the fully dimensionalmodel.
The second critical point is also explained easilywhen assuming
this model. Those genetic loci most strongly associated with the
distinction between cases and controls cannot be associated with
high schizotypy within healthy individuals. In fact, and this has
been shown [e.g., Ref. (31, 32)], they must be inversely related to
schizotypy or related measures (like psychosis-like experiences).
In other words, should a person high in (especially positive)
schizotypy additionally carry substantial numbers of alleles that
distinguish between cases and controls (and, thus, probably load
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on the aforementioned dimension resilience), this person would
not be found in a healthy sample. Furthermore, increasingly high
levels of schizotypy must, in healthy individuals, coincide with
increasingly lower genetic factors conveying risk for schizophre-
nia (i.e., with higher resilience).
To summarize and in conclusion, at first glance, schizotypy
meets all the criteria as proposed by Gottesman and Gould (16)
for endophenotypes in psychiatry. One could, thus, stop here
and consider schizotypy in general a suitable endophenotype
of schizophrenia. This might be jumping the gun, however, as,
upon closer examination, there are a number of discrepancies
between schizotypy and schizophrenia; especially related to genet-
ics and the distinction between positive and negative/disorganized
traits. I would, therefore, suggest (sensu 30) that (high) positive
schizotypy be better described as an endophenotype of psychosis-
in-schizophrenia (as well as in other psychiatric conditions or
the otherwise healthy), while (high) negative schizotypy may be
viewed upon as an endophenotype of schizophrenia-in-psychosis
(i.e., tappingmore intoKrankheitswert). The latter is important, as
(high) negative schizotypy is not exclusive to psychotic disorders,
but also found to share considerable variance with another per-
sonality trait linked to other (e.g., affective or anxiety) disorders;
i.e., Neuroticism (33). Schizophreniawould, thus, be considered as
the overlap of (very) high positive and negative schizotypy. This
interaction between different aspects of personality (and inherent
cognitive patterns) regarding the development of schizophrenia
has been clearly shown by Gaweda and Prochwicz (34): while
a cognitive bias typically associated with positive schizotypy
(jumping to conclusions) did not differ between highly delusion-
prone healthy controls and delusional schizophrenics, another
bias strongly associated with negative schizotypy (catastrophiz-
ing) clearly differentiated both groups of patients (schizophrenics
with and without delusions) from both groups of healthy controls
(high and low delusion-proneness).
This makes schizotypy no less useful in schizophrenia research,
however. I would state that it actually strengthens the case made
by schizotypy researchers when saying that it is a useful and
“the most influential, comprehensive psychological construct in
schizophrenia research” [(35); p. S363; my emphasis]. This is quite
simply due to the fact that in schizophrenia genetics it is not clear
with what the identified genes are actually associated (proneness
for psychosis or risk for schizophrenia; i.e., illness), whereas this
is not the case in schizotypy. In other words, accepting dis-
crete facets of schizotypy per se as suitable endophenotypes of
psychosis-in-schizophrenia vs. schizophrenia-in-psychosis may not
only help researching the (biological) basis of psychosis in eneral
(including, of course, psychosis-in-schizophrenia), but also help
us examine why certain (highly schizotypic) individuals develop
schizophrenia while others benefit from their perceived “odd-
ness.” Schizotypy research is, in my opinion, better suited for both
aforementioned aspects of schizophrenia research than simple
case–control designs both due to the possibility of differentiation
between individual schizotypic facets and due to schizotypy’s nat-
urally dimensional nature compared to the (artificial) dichotomy
in the comparison between schizophrenic patients and “healthy”
controls.
References
1. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am Psychol (1962)
17:827–38. doi:10.1037/h0041029
2. Lenzenweger MF. Schizotypy – an organizing framework for schizophrenia
research. Curr Dir Psychol (2006) 15:162–6. doi:10.1093/schbul/sbu195
3. Grant P. Genetic associations: the basis of schizotypy. In: Mason O, Claridge
G, editors. Schizotypy – New Dimensions. London: Routledge, Taylor & Francis
Group (2015).
4. Barrantes-Vidal N, Grant P, Kwapil TR. The role of schizotypy in the Study
of the Etiology of Schizophrenia Spectrum Disorders. Schizophr Bull (2015)
41:S408–16. doi:10.1093/schbul/sbu191
5. Vollema MG, van den Bosch RJ. The multidimensionality of schizotypy.
Schizophr Bull (1995) 21:19–31. doi:10.1093/schbul/21.1.19
6. Kwapil TR, Barrantes-Vidal N, Silvia PJ. The dimensional structure of the Wis-
consin schizotypy scales: factor identification and construct validity. Schizophr
Bull (2008) 34:444–57. doi:10.1093/schbul/sbm098
7. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in
schizophrenia: a selective review. Schizophr Res (2009) 109:24–37. doi:10.1016/
j.schres.2009.01.016
8. Ettinger U, Mohr C, Gooding DC, Cohen AS, Rapp A, Haenschel C, et al.
Cognition and brain function in schizotypy: a selective review. Schizophr Bull
(2015) 41:S417–26. doi:10.1093/schbul/sbu190
9. Grant P, Kuepper Y, Mueller E, Wielpuetz C, Mason O, Hennig J. Dopaminergic
foundations of schizotypy as measured by the German version of the oxford-
liverpool inventory of feelings and experiences (O-LIFE) – a suitable endophe-
notype of schizophrenia. Front Hum Neurosci (2013) 7:1. doi:10.3389/fnhum.
2013.00001
10. Jackson M. Bening schizotypy? The case of spiritual experience. In: Claridge
G, editor. Schizotypy – Implications for Illness and Health. Oxford: Oxford
University Press (1997). p. 227–50.
11. Hay D. Exploring Inner Space, Penguin. Harmondsworth: Penguin (1987).
12. Mohr C, Claridge G. Schizotypy-do not worry, it is not all worrisome. Schizophr
Bull (2015) 41:S436–43. doi:10.1093/schbul/sbu185
13. McCreery C. Hallucinations and arousability: pointers to a theory of psychosis.
In: Claridge G, editor. Schizotypy – Implications for Illness and Health. Oxford:
Oxford University Press (1997). p. 251–73.
14. Tarbox SI, Pogue-Geile MF. A multivariate perspective on schizotypy and
familial association with schizophrenia: a review. Clin Psychol Rev (2011)
31:1169–82. doi:10.1016/j.cpr.2011.07.002
15. Linney YM, Murray RM, Peters ER, MacDonald AM, Rijsdijk F, Sham PC.
A quantitative genetic analysis of schizotypal personality traits. Psychol Med
(2003) 33:803–16. doi:10.1017/S0033291703007906
16. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology
and strategic intentions. Am J Psychiatry (2003) 160:636–45. doi:10.1176/appi.
ajp.160.4.636
17. Hodgekins J, Coker S, Freeman D, Ray-Glover K, Bebbington P, Garety P,
et al. Assessing levels of subthreshold psychotic symptoms in the recovery
phase: the schizotypal symptoms inventory (SSI). J Exp Psychopathol (2012) 3:
582–93. doi:10.5127/jep.021211
18. Heron J, Jones I, Williams J, Owen MJ, Craddock N, Jones LA. Self-reported
schizotypy and bipolar disorder: demonstration of a lack of specificity of the
kings schizotypy questionnaire. Schizophr Res (2003) 65:153–8. doi:10.1016/
S0920-9964(03)00004-5
19. Mason O, Claridge G. The oxford-liverpool inventory of feelings and experi-
ences (O-LIFE): further description and extended norms. Schizophr Res (2006)
82:203–11. doi:10.1016/j.schres.2005.12.845
20. Barrantes-Vidal N, Chun CA, Myin-Germeys I, Kwapil TR. Psychometric
schizotypy predicts psychotic-like, paranoid, and negative symptoms in daily
life. J Abnorm Psychol (2013) 122:1077–87. doi:10.1037/a0034793
21. Battaglia M, Gasperini M, Sciuto G, Scherillo P, Diaferia G, Bellodi L. Psy-
chiatric disorders in the families of schizotypal subjects. Schizophr Bull (1991)
17:659–68. doi:10.1093/schbul/17.4.659
22. Kendler KS, Walsh D. Schizotypal personality disorder in parents and the
risk for schizophrenia in siblings. Schizophr Bull (1995) 21:47–52. doi:10.1093/
schbul/21.1.47
23. Glahn DC, Blangero J. Why endophenotype development requires families.
Chin Sci Bull (2011) 56:3382–4. doi:10.1007/s11434-011-4740-4
Frontiers in Psychiatry | www.frontiersin.org October 2015 | Volume 6 | Article 1433
Grant Schizotypy as endophenotype of schizophrenia
24. Claridge G. Theoretical background and issues. In: Claridge G, editor. Schizo-
typy – Implications for Illness and Health. Oxford: Oxford University Press
(1997). p. 3–18.
25. Grant P, Munk AJL, Kuepper Y, Wielpuetz C, Hennig J. Additive
genetic effects for schizotypy support a fully-dimensional model of
psychosis-proneness. J Individ Differ (2015) 36:87–92. doi:10.1027/1614-
0001/a000155
26. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, et al.
Genome-wide association analysis identifies 13 new risk loci for schizophrenia.
Nat Genet (2013) 45:1150–9. doi:10.1038/ng.2742
27. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Bio-
logical insights from 108 schizophrenia-associated genetic loci. Nature (2014)
511:421–7. doi:10.1038/nature13595
28. Eysenck HJ. The definition and measurement of psychoticism. Pers Individ Dif
(1992) 13:757–85. doi:10.1016/0191-8869(92)90050-Y
29. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits.
Nat Rev Genet (2009) 10:872–8. doi:10.1038/nrg2670
30. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III –
the final common pathway. Schizophr Bull (2009) 35:549–62. doi:10.1093/
schbul/sbp006
31. Zammit S, Hamshere M, Dwyer S, Georgiva, L, Timpson, N, Moskvina V, et al.
A population-based study of genetic variation and psychotic experiences in
adolescents. Schizophr Bull (2014) 40(6):1254–62. doi:10.1093/schbul/sbt146
32. Hatzimanolis, et al. Personal communication from Nikolaos Smyrnis.
(Forthcoming).
33. Macare C, Bates CB, Heath AC, Martin NG, Ettinger U. Substantial genetic
overlap between schizotypy and neuroticism: a Twin Study. Behav Genet (2012)
42:732–42. doi:10.1007/s10519-012-9558-6
34. Gaweda L, Prochwicz K. A comparison of cognitive biases between schizophre-
nia patients with delusions and healthy controls with delusion-like experiences.
Eur Psychiatry (2015) 30:943–9.
35. Debbane M, Mohr C. Integration and development in schizotypy research:
an introduction to the special supplement. Schizophr Bull (2015) 41:S363–5.
doi:10.1093/schbul/sbv003
Conflict of Interest Statement: The author declares that this research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Grant. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org October 2015 | Volume 6 | Article 1434
